✦ LIBER ✦

Dose escalation study of carboplatin with fixed-dose etoposide plus granulocyte-colony stimulating factor in patients with small cell lung carcinoma: A study of the Lung Cancer Study Group of West Japan

Book ID: 121905581
Publisher: Elsevier Science
Year: 1996
Tongue: English
Weight: 144 KB
Volume: 15
Category: Article
ISSN: 0169-5002
DOI: 10.1016/0169-5002(96)84382-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dose escalation study of carboplatin wit

Dose escalation study of carboplatin with fixed-dose etoposide plus granulocyte-colony stimulating factor in patients with small cell lung carcinoma: A study of the lung cancer study group of west Japan

✍ Nobuyuki Katakami; Minoru Takada; Shunichi Negoro; Katsuyasu Ota; Jiro Fujita; K 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 738 KB

## BACKGROUND. We performed a Phase 1-11 trial to determine the maximum tolerated dose of carboplatin (CBDCA) with a fixed dose of VP-16 and granulocyte-colony stimulating factor (G-CSF) in small cell lung cancer (SCLC) patients. ## METHODS. Treatment consisted of a starting dose of CBDCA, 400

Ifosfamide, carboplatin, and etoposide p

Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony- stimulating factor: A phase I study with apparent activity in non-small-cell lung cancer

📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 273 KB

A study of dose escalation of teniposide

A study of dose escalation of teniposide (VM-26) plus cisplatin (CDDP) with recombinant human granulocyte colony-stimulating factor (rhG-CSF) in patients with advanced small cell lung cancer

✍ Eguchi, Kenji; Etou, Hisashi; Miyachi, Sumiki; Morinari, Hajime; Nakada, Kouichi 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 982 KB

Phase III study of carboplatin and oral

Phase III study of carboplatin and oral etoposide with granulocyte- colony stimulating factor in advanced nonsmall cell lung cancer

📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 137 KB

Dose escalation study of carboplatin (CB

Dose escalation study of carboplatin (CBDCA) and etoposide (VP-16) with G-CSF in small cell lung cancer (SCLC)

📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 162 KB

Phase I/II study of carboplatin and oral

Phase I/II study of carboplatin and oral etoposide with granulocyte-colony stimulating factor in advanced nonsmall cell lung cancer

✍ Giuseppe Frasci; Giovanni Persico; Giuseppe Perillo; Giuseppe Comella; Pasquale 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 665 KB

Background. A combination of carboplatin (CBDCA) and oral etoposide is better tolerated than, and as effective as, more aggressive chemotherapy regimens in patients with advanced nonsmall cell lung cancer (NSCLC). A Phase 1/11 study was conducted to determine whether the addition of the granulocyte-